FRE Stock Overview
Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Firebrick Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.065 |
| 52 Week High | AU$0.36 |
| 52 Week Low | AU$0.036 |
| Beta | 1.82 |
| 1 Month Change | 30.00% |
| 3 Month Change | 22.64% |
| 1 Year Change | -66.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -87.74% |
Recent News & Updates
Recent updates
Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation
Aug 14
We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
May 02We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
Dec 14Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth
Aug 30Shareholder Returns
| FRE | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -17.7% | -1.7% | 0.9% |
| 1Y | -66.7% | 31.3% | 5.6% |
Return vs Industry: FRE underperformed the Australian Pharmaceuticals industry which returned 31.3% over the past year.
Return vs Market: FRE underperformed the Australian Market which returned 5.6% over the past year.
Price Volatility
| FRE volatility | |
|---|---|
| FRE Average Weekly Movement | 18.1% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: FRE's share price has been volatile over the past 3 months.
Volatility Over Time: FRE's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Peter Molloy | www.firebrickpharma.com |
Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Firebrick Pharma Limited Fundamentals Summary
| FRE fundamental statistics | |
|---|---|
| Market cap | AU$11.63m |
| Earnings (TTM) | -AU$4.57m |
| Revenue (TTM) | AU$1.82m |
6.4x
P/S Ratio-2.5x
P/E RatioIs FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE income statement (TTM) | |
|---|---|
| Revenue | AU$1.82m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.82m |
| Other Expenses | AU$6.39m |
| Earnings | -AU$4.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 100.00% |
| Net Profit Margin | -251.57% |
| Debt/Equity Ratio | 0% |
How did FRE perform over the long term?
See historical performance and comparison